ASCENTAGE PHARMA GROUP(AAPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AAPG ASCENTAGE PHARMA GROUP

Market Closed 02-27 16:00:00 EST

24.10

+0.00

0.00%

盘后24.10

+0.000.00%

16:10 EST

High24.10	Low24.10	Vol167.00
Open24.10	D1 Closing24.10	Amplitude0.00%
Mkt Cap2.25B	Tradable Cap1.73B	Total Shares93.33M
T/O4.04K	T/O Rate0.00%	Tradable Shares71.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"ASCENTAGE PHARMA GROUP","latestPrice":24.1,"timestamp":1772226000000,"preClose":24.1,"halted":0,"volume":167,"hourTrading":{"tag":"盘后","latestPrice":24.1,"preClose":24.1,"latestTime":"16:10 EST","volume":4,"amount":94.48,"timestamp":1772226604055,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"Market Closed","change":0,"latestTime":"02-27 16:00:00 EST","open":24.1,"high":24.1,"low":24.1,"amount":4035.0382,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":24.1,"postHourTrading":{"tag":"盘后","latestPrice":24.1,"preClose":24.1,"latestTime":"16:10 EST","volume":4,"amount":94.48,"timestamp":1772226604055,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.1513229211565174},"requestUrl":"/m/hq/s/AAPG/wiki","defaultTab":"wiki","newsList":[{"id":"2613978243","title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613978243","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613978243?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Feb.  23, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”),a global, commercial stage, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242582/0/en/Ascentage-Pharma-to-Participate-in-Three-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2610729653","title":"Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610729653","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610729653?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:00","pubTimestamp":1770642000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Feb.  09, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company, a global, commercial stage, i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234476/0/en/Ascentage-Pharma-to-Participate-in-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","AAPG","BK4139","SMMF","BK4211","BK4588","LABU"],"gpt_icon":0},{"id":"2609569413","title":"Ascentage Pharma Says Bruton's Tyrosine Kinase-Targeted Protein Degrader Application Gets China Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2609569413","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609569413?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:52","pubTimestamp":1770371561,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (AAPG) said late Thursday that China Center for Drug Evaluation cleared the company's investigational new drug application for Bruton's tyrosine kinase-targeted pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2609533250","title":"Ascentage Pharma announces IND clearance by the China CDE for APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533250","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533250?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:35","pubTimestamp":1770334517,"startTime":"0","endTime":"0","summary":"Ascentage Pharma (AAPG) “announced that its novel next-generation Bruton’s tyrosine kinase-targeted protein degrader, APG-3288, has received invest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-announces-ind-clearance-by-the-china-cde-for-apg-3288-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-announces-ind-clearance-by-the-china-cde-for-apg-3288-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1223083913.SGD","LU1223082196.USD","LU1223082519.USD","LU1923622291.USD","CDE","BK4129","BK4017","IND","BK4139","LU2125909759.SGD","APG","AAPG","LU2125909916.SGD"],"gpt_icon":0},{"id":"2609533068","title":"Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533068","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533068?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:30","pubTimestamp":1770334200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233530/0/en/Ascentage-Pharma-Announces-IND-Clearance-by-the-China-CDE-for-BTK-Degrader-APG-3288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0124676726.USD","WM","LU2298064838.USD","LU2125909916.SGD","LU2362541513.USD","BK4585","LU1223083913.SGD","BCR","LU0057025933.USD","LU2111349929.HKD","LU1223082196.USD","LU0289960550.SGD","LU2463526074.USD","LU1430594728.SGD","LU2041044095.USD","LU2271345857.HKD","LU1917777945.USD","LU1923622291.USD","LU1923621640.USD","BK4181","LU1892829315.USD","LU0289739343.SGD","LU2308191902.HKD","LU2362540622.SGD","LU1939255532.USD","LU2089284900.SGD","LU0511384066.AUD","AAPG","LU2106854487.HKD","PK","APG","IND","LU2089283258.USD","LU1989772923.USD","LU2238339852.HKD","BK4588","LU0158827948.USD","LU2240825500.USD","LU0347712357.USD","LU2023251221.USD","LU2413666426.HKD","LU0472753341.HKD","LU1712237335.SGD","CDE","LU1989772840.SGD","LU2023250504.SGD","LU2125909759.SGD","LU2413666699.HKD","BK4139"],"gpt_icon":0},{"id":"1128142501","title":"ASCENTAGE-B Stock Surges Over 3% in Intraday Trading as BTK Degrader Class 1 New Drug APG-3288 Tablets Gain Clinical Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1128142501","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128142501?lang=en_us&edition=fundamental","pubTime":"2026-02-04 11:12","pubTimestamp":1770174738,"startTime":"0","endTime":"0","summary":"Shares of ASCENTAGE PHARMA GROUP - B (06855) climbed more than 3% during the trading session. At the time of writing, the stock was up 1.38%, trading at HK$45.88, with a turnover of HK$36.975...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","APG","BK4129","LU2125909916.SGD","LU1923622291.USD","BK1161","LU2125909759.SGD","BK4139","BK1574","06855"],"gpt_icon":0},{"id":"2603216076","title":"Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603216076","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603216076?lang=en_us&edition=fundamental","pubTime":"2026-01-15 09:25","pubTimestamp":1768440300,"startTime":"0","endTime":"0","summary":"Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives IND clearance f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/15/3219202/0/en/Ascentage-Pharma-Outlined-its-Global-Innovation-Strategy-During-Presentation-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225283273.USD","LU0106261372.USD","LU1162221912.USD","LU1244550577.SGD","BK4127","BK4581","IE00BKVL7J92.USD","XBI","LU1720051108.HKD","BK4139","LABU","LU1548497426.USD","LU0267386448.USD","LU0029874061.USD","LU0314104364.USD","LU1732800096.USD","BK4137","LU0882574139.USD","LU1791710582.SGD","LU2028103732.USD","BK4585","IND","LU1363072403.SGD","BK4534","HCSG","AAPG","LU0795875086.SGD","LU1074936037.SGD","LU1668664300.SGD","LU2347655156.SGD","LU1989772923.USD","LU2111349929.HKD","IE00BZ1G4Q59.USD","LU2133065610.SGD","LU0912757837.SGD","LU2089283258.USD","LU1244550494.USD","LU0158827948.USD","LU0234570918.USD","LU0795875169.SGD","LU0128526141.USD","LU1732799900.SGD","XLV","LU2271345857.HKD","LU0006306889.USD","BK4588","LU1989772840.SGD","LU0158827781.USD","LU1791710400.SGD","LU2089284900.SGD"],"gpt_icon":0},{"id":"2603598630","title":"Ascentage Pharma initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2603598630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603598630?lang=en_us&edition=fundamental","pubTime":"2026-01-14 04:20","pubTimestamp":1768335631,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $48 price target Published first on TheFly – the ultimate sour...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2601369153","title":"Piper Sandler Reaffirms Their Buy Rating on Ascentage Pharma Group International Unsponsored ADR (AAPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369153?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:17","pubTimestamp":1767874648,"startTime":"0","endTime":"0","summary":"In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Ascentage Pharma Group International Unsponsored ADR, with a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-ascentage-pharma-group-international-unsponsored-adr-aapg-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-ascentage-pharma-group-international-unsponsored-adr-aapg-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAPG"],"gpt_icon":0},{"id":"2601314871","title":"Ascentage Pharma Gets FDA's IND Clearance for APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601314871","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601314871?lang=en_us&edition=fundamental","pubTime":"2026-01-07 18:12","pubTimestamp":1767780754,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group (AAPG) said late Tuesday it has received an investigational new drug clearance from the US Food and Drug Administration for oncology drug candidate APG-3288.The company plans to advance the drug into a phase 1 trial in patients with relapsed/refractory B-cell malignancies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2125909916.SGD","IND","APG","LU1923622291.USD","LU2125909759.SGD","BK4139","AAPG","BK4129"],"gpt_icon":0},{"id":"1146349455","title":"Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=1146349455","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146349455?lang=en_us&edition=fundamental","pubTime":"2026-01-07 11:10","pubTimestamp":1767755435,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) rose nearly 4%, and as of the time of writing, it was up 3.69% to HK$53.4, with a turnover of HK$61.6418 million.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APG","06855","BK1574","LU2125909916.SGD","LU1923622291.USD","AAPG","BK1161","LU2125909759.SGD","BK4139","BK4129"],"gpt_icon":0},{"id":"2601479768","title":"Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601479768","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601479768?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:00","pubTimestamp":1767747600,"startTime":"0","endTime":"0","summary":"Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has receivedinvestigational new drug (IND) clearancefrom the U.S. FDA, marking another major expansion to the comp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214213/0/en/Ascentage-Pharma-Announces-IND-Clearance-by-the-U-S-Food-and-Drug-Administration-for-BTK-Degrader-APG-3288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909916.SGD","LU2229751404.USD","LU2041044095.USD","LU1430594728.SGD","LU1989772840.SGD","BK4129","LU2125910336.SGD","LU0057025933.USD","PK","WM","IND","LU2125910179.SGD","BK4585","LU0289961442.SGD","LU2089279066.USD","LU1939255532.USD","LU2023250504.SGD","BK4120","LU2240825500.USD","BK4588","LU2211814178.USD","LU2308191902.HKD","LU1917777945.USD","LU2238339852.HKD","LU2125909759.SGD","LU2355687059.USD","LU0472753341.HKD","LU1892829315.USD","LU1712237335.SGD","LU2362541513.USD","LU1623119135.USD","BCR","BK4181","LU0689626769.HKD","LU1923621640.USD","LU1923622291.USD","BK4139","APG","LU1974910355.USD","LU0289739343.SGD","LU0124676726.USD","LU2413666699.HKD","LU1585245621.USD","AAPG","LU0069063385.USD","LU2362540622.SGD","BK4534","LU0511384066.AUD","LU0347712357.USD","BK4533"],"gpt_icon":0},{"id":"1168013082","title":"ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1168013082","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168013082?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:50","pubTimestamp":1767106220,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA GROUP-B (06855) announced that Dr. Debra Yu will be appointed as an additional member of the Board Nomination Committee, effective December 26, 2025. Dr. David Sidransky will be...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK4139","AAPG","06855"],"gpt_icon":0},{"id":"1177837504","title":"CICC Maintains \"Outperform\" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU","url":"https://stock-news.laohu8.com/highlight/detail?id=1177837504","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177837504?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:57","pubTimestamp":1765943833,"startTime":"0","endTime":"0","summary":"CICC has reiterated its \"Outperform\" rating on ASCENTAGE-B (06855) with a target price of HK$89, citing positive progress in the company's R&D pipeline. The global Phase III study (POLARIS-1) for...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4139","AAPG","BK1574","06855"],"gpt_icon":0},{"id":"2590677273","title":"ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590677273","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590677273?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapyMolecular responses continue to deepen with extended treatment duration, reaching 60% m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202020/0/en/ASH-2025-Updated-Data-for-Ascentage-Pharma-s-Olverembatinib-in-Second-Line-CML-CP-Showing-Encouraging-Potential-for-Early-Line-Treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1261432733.SGD","LU2463526074.USD","BK4588","BK4016","BK4109","ASH","BK4585","BK4139","AAPG","CP"],"gpt_icon":0},{"id":"2590367742","title":"ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367742","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590367742?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectivelyHigh-risk IKZF1plus patient","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202021/0/en/ASH-2025-Ascentage-Pharma-Presents-First-Dataset-from-Phase-III-POLARIS-1-Study-of-Olverembatinib-in-Newly-Diagnosed-Ph-ALL-Shows-a-Best-MRD-Negativity-CR-Rate-Exceeding-60.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALL","CR","EMA","BK4081","BK4588","LU2463526074.USD","BK4585","BK4107","ASH","BK4134","LU0985320562.USD","III","AAPG","BK4161","BK4109","LU1571399168.USD","BK4139","BK4533","LU1699723380.USD","LU2355687059.USD"],"gpt_icon":0},{"id":"2590367726","title":"ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367726","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590367726?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effect","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202022/0/en/ASH-2025-Ascentage-Pharma-Presents-Four-Year-Follow-Up-Data-from-Registrational-Phase-II-Study-of-Olverembatinib-Reaffirming-Differentiated-Long-Term-Efficacy-and-Safety-in-TKI-Res.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","BK4139","BK4077","BK4109","BK4585","CHR","BK4016","AAPG","BK4588","CP","LU1261432733.SGD","LU2463526074.USD"],"gpt_icon":0},{"id":"2589807890","title":"ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances","url":"https://stock-news.laohu8.com/highlight/detail?id=2589807890","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589807890?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:10","pubTimestamp":1765156200,"startTime":"0","endTime":"0","summary":"Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201167/0/en/ASH-2025-Ascentage-Pharma-Presents-Encouraging-Data-from-Phase-Ib-II-Study-of-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Exposed-Patients-with-Myeloid-Malignances.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","ASH","BK4139","LU2463526074.USD","BK4097","AAPG","BK4203","BK4109","OS","HR","BK4225"],"gpt_icon":0},{"id":"2589066826","title":"Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589066826","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589066826?lang=en_us&edition=fundamental","pubTime":"2025-12-06 23:15","pubTimestamp":1765034100,"startTime":"0","endTime":"0","summary":"Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201070/0/en/Ascentage-Pharma-Presents-Pivotal-China-Registrational-Study-Data-for-Lisaftoclax-in-Oral-Report-at-2025-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","LU2463526074.USD","ORR","BK4097","BK4139","BK4203","BK4225","AAPG","TLS","BK4109","HR","AFG","ASH","BK4117"],"gpt_icon":0},{"id":"1170778758","title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 6% as POLARIS-1 Study for Olverembatinib (Nerlynx®) Gains FDA and EMA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1170778758","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170778758?lang=en_us&edition=fundamental","pubTime":"2025-12-05 09:38","pubTimestamp":1764898699,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) surged more than 6%, reaching HK$64.2 by the time of writing, with a trading volume of HK$19.93 million. The uptick follows the company's announcement on December 5 that its...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4139","AAPG","BK4081","BK1574","06855","EMA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentage.com","stockEarnings":[{"period":"1week","weight":-0.0333},{"period":"1month","weight":-0.0474},{"period":"3month","weight":-0.2585},{"period":"6month","weight":-0.4325},{"period":"1year","weight":0.2172},{"period":"ytd","weight":-0.0816}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"ASCENTAGE PHARMA GROUP","nameEN":"ASCENTAGE PHARMA GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ASCENTAGE PHARMA GROUP(AAPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ASCENTAGE PHARMA GROUP(AAPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ASCENTAGE PHARMA GROUP,AAPG,ASCENTAGE PHARMA GROUP股票,ASCENTAGE PHARMA GROUP股票老虎,ASCENTAGE PHARMA GROUP股票老虎国际,ASCENTAGE PHARMA GROUP行情,ASCENTAGE PHARMA GROUP股票行情,ASCENTAGE PHARMA GROUP股价,ASCENTAGE PHARMA GROUP股市,ASCENTAGE PHARMA GROUP股票价格,ASCENTAGE PHARMA GROUP股票交易,ASCENTAGE PHARMA GROUP股票购买,ASCENTAGE PHARMA GROUP股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ASCENTAGE PHARMA GROUP(AAPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ASCENTAGE PHARMA GROUP(AAPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction